Assembly Biosciences said the decision was “not based on any efficacy, ... The 21-year-old, New York-based biotech announced Phase I data for its gene ... unveiled Wednesday at the virtual San Antonio Breast Cancer Symposium.
News
- News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand ...
- RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and ...
The biotech says that the cell-penetrating nature of the peptides, when ... unveiled Wednesday at the virtual San Antonio Breast Cancer Symposium.
- PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
The results were presented at the SABCS (San Antonio Breast Cancer ... PharmAbcine is a clinical-stage biotech company focusing on the ...
- BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB: BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for ...
- Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer ...
... ongoing Phase 1/2 clinical trial for BDC-1001 in patients with HER2-expressing solid tumors at the San Antonio Breast Cancer Symposium (SABCS) ...